American Lung Association Urges Fall Vaccinations Against Respiratory Viruses

With the fall season arriving and the typical increase in respiratory viruses such as influenza, COVID-19, and RSV, the American Lung Association is calling on the public to consult with healthcare providers about recommended vaccinations. The organization aims to educate individuals with lung disease and other at-risk groups about the critical role of vaccines in preventing severe illness and hospitalizations.

Recent data underscores the significant burden of respiratory viruses. For the 2025-2026 influenza season, an estimated 32 million illnesses, 390,000 hospitalizations, and 24,000 deaths were recorded. COVID-19 contributed millions of outpatient visits and hundreds of thousands of hospitalizations during the same period. Respiratory Syncytial Virus (RSV) also poses a substantial threat, with hundreds of thousands of hospitalizations estimated.

"Vaccines are effective and help keep people healthy and out of the hospital. They are especially important for individuals with lung disease, as respiratory infections can worsen existing symptoms," stated Harold Wimmer, President and CEO of the American Lung Association. He emphasized that vaccination is the best protection heading into the winter months.

The American Lung Association recommends discussing the following vaccines with a healthcare professional: an annual flu shot for everyone six months and older, COVID-19 vaccination (in consultation with a provider), and the RSV vaccine for adults aged 50-74 at increased risk of severe RSV illness (including those with chronic lung or heart conditions), as well as all adults aged 75 and older who have not previously received the vaccine.

For individuals with conditions like asthma, lung cancer, or COPD, respiratory viruses present a heightened risk. These infections can exacerbate lung disease symptoms, increase the likelihood of hospitalization, and prolong recovery.